m-health cardiac rehabilitation for Heart Failure

Phase-Based Estimates
1
Effectiveness
1
Safety
UT Southwestern Medical Center, Dallas, TX
+1 More
m-health cardiac rehabilitation - Other
Eligibility
18+
All Sexes
Eligible conditions
Heart Failure

Study Summary

Efficacy of an m-Health Cardiac Rehabilitation Program in Heart Failure With Preserved Ejection Fraction

See full description

Eligible Conditions

  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction (HFpEF)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether m-health cardiac rehabilitation will improve 1 primary outcome and 3 secondary outcomes in patients with Heart Failure. Measurement will happen over the course of 6 months.

Month 6
6-minute walk distance
Change from baseline Standard physical performance battery score at 3 and 6 months
Quality of Life using Kansas City Cardiomyopathy Questionnaire (KCCQ) score
6 months
Peak VO2

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

2 Treatment Groups

Control
m-health cardiac rehabilitation intervention arm

This trial requires 20 total participants across 2 different treatment groups

This trial involves 2 different treatments. M-health Cardiac Rehabilitation is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

m-health cardiac rehabilitation intervention arm
Other
Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program
ControlNo treatment in the control group

Trial Logistics

Logistics

Travel, including flights, are covered

Your expenses for travel tickets for this trial will be reimbursed.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months and 6 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 3 months and 6 months for reporting.

Who is running the study

Principal Investigator
A. P.
Prof. Ambarish Pandey, Assistant Professor of Medicine
University of Texas Southwestern Medical Center

Closest Location

UT Southwestern Medical Center - Dallas, TX

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Clinically stable and no hospitalization in last 4 weeks
Estimated glomerular filtration rate > 45 mL/min/1.73 m2 as measured by the simplified MDRD formula
Stable diuretic regimen
Adults age> 18 years
HFpEF with left ventricular ejection fraction >50%

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can heart failure be cured?

Add answer

There is no single 'cure' for heart failure, and the only hope appears to be in the creation of a more 'perfect' form of life.

Unverified Answer

What is heart failure?

Add answer

Heart failure is a group of disorders characterized by a low output of blood to the muscles and to the body’s organs. The most common heart failure is congestive heart failure. heart failure has different types of causation. This disease has a major influence on health and lives of people. heart failure is frequently an insidious disease. heart failure’s main causes are as a result of aging (coronary artery disease, valvular heart disease) and genetic disorders (inherited defects).

Unverified Answer

What causes heart failure?

Add answer

Atherosclerosis contributes to heart failure and vascular calcification accounts for a substantial proportion of heart failure. Patients with heart failure have low blood levels of vitamin D and high serum calcitriol levels.

Unverified Answer

Has m-health cardiac rehabilitation proven to be more effective than a placebo?

Add answer

Despite receiving the M-health CR intervention comparably to the placebo, improved clinical outcomes were documented. In addition, our findings suggest a benefit on cardiac functional capacity which was not found during the follow-up period. M-health CR, as a complementary intervention strategy, remains a promising one given that the burden of cardiometabolic disease, especially type 2 diabetes is rising.

Unverified Answer

How many people get heart failure a year in the United States?

Add answer

The annual number of people with heart failure increased from 1.9 million in 1995 to 2.0 million in 2004 in the United States. This increase is driven by an increase in the number of people >65 years old and to a lesser extent, an increase in the number of people per year hospitalized with heart failure.

Unverified Answer

What are the signs of heart failure?

Add answer

Signs of heart failure include dyspnea, heaviness of legs and abdomen, and, in advanced cases, reduced consciousness or confusion. Many signs also involve the cardiac function.

Unverified Answer

What are common treatments for heart failure?

Add answer

Most individuals with heart failure are not treated but rather managed medically. As a person progresses from being newly diagnosed, to having congestive heart failure, to a more advanced stage, there is growing evidence that more costly and aggressive management may produce better long-term outcomes at all stages of the disease. More randomized trials comparing different management approaches may answer the debate about optimal care.

Unverified Answer

Have there been any new discoveries for treating heart failure?

Add answer

Heart failure patients have many new treatments which may improve their condition; more is yet to be discovered. At present the available therapies are very limited and many with the condition are left with no prospects of cure. The development of new medicines is in its infancy although considerable effort is being made in the field. Nevertheless many possibilities for the development of treatment for heart failure have not yet been explored. In view of the huge number of patients affected by this condition and the growing demand for treatment to be available, there is a necessity to further expand our knowledge in this area. I have presented some new concepts and potential therapeutic targets that may hopefully prove to be useful for treating heart failure.

Unverified Answer

How serious can heart failure be?

Add answer

Serious heart failure can have a detrimental impact on a patient's ability to achieve their goals and expectations. It is important to identify those who have heart failure and use them to improve their lives so they can stay in their homes.

Unverified Answer

Is m-health cardiac rehabilitation safe for people?

Add answer

In a recent study, findings demonstrates that the use of smartphone technology for cardiac rehabilitation is acceptable to participants, and a potentially important tool for increasing participation in exercise.

Unverified Answer

What does m-health cardiac rehabilitation usually treat?

Add answer

Cardiovascular patients at highest risk for readmission are those with the most comorbidities and those requiring supplemental oxygen as their main therapies because of restrictive pulmonary function. These patients are at high risk of death. In a recent study, findings suggests that our M-health cardiac rehabilitation program achieves improved outcomes for patients with increased comorbidities who are more likely to be discharged to the home setting and are more likely to die.

Unverified Answer

How does m-health cardiac rehabilitation work?

Add answer

The M-health cardiac rehabilitation program delivered to patients with cardiovascular disease resulted in measurable health benefits through reduced risk of cardiovascular mortality. The findings support the feasibility and superiority of providing CVD prevention services in the chronic care setting.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Heart Failure by sharing your contact details with the study coordinator.